Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669028 | 0.87 | TDP1 (0.49) | TDP1MAPTAKR1B1AKR1B10TSHR | |
| SCHEMBL4143335 | 0.86 | TDP1 (0.70) | TDP1MAPTTSHRPTGDR2KDM4E | |
| SCHEMBL12100682 | 0.84 | TDP1 (0.46) | TDP1MAPTAKR1B1AKR1B10TSHR | |
| SCHEMBL20355260 | 0.84 | TDP1 (0.60) | TDP1MAPTAKR1B1AKR1B10TSHR | |
| SCHEMBL5389347 | 0.84 | TDP1 (0.77) | TDP1MAPTTSHRPTGDR2PTGDR | |
| SCHEMBL4675125 | 0.83 | POLB (0.52) | TDP1MAPTAKR1B1AKR1B10TSHR | |
| SCHEMBL1546386 | 0.83 | TSHR (0.52) | MAPTTSHRKDM4ECASP1SMN1; SMN2 | |
| SCHEMBL64347 | 0.82 | TDP1 (0.74) | TDP1MAPTTSHRPTGDR2PTGDR | |
| SCHEMBL9187673 | 0.81 | TSHR (0.50) | MAPTTSHRKDM4ECASP1SMN1; SMN2 | |
| SCHEMBL13951660 | 0.81 | TSHR (0.50) | MAPTTSHRPTGDR2CASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380751-B | Indanamine derivatives, preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-114380751-A | Indane amine derivatives, preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114315736-A | Indane amine derivatives, preparation method and application thereof | 甫康（上海）健康科技有限责任公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-2681207-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2681207-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012119046-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012119046-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7235569-B2 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | TPH1, TPH2, HTR3A | TDP1 494/4885MAPT 1405/4885AKR1B1 4015/4885 |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | TDP1 909/4885MAPT 643/4885AKR1B1 4330/4885 |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | TDP1 2483/4885MAPT 3629/4885AKR1B1 1447/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | TDP1 909/4885MAPT 643/4885AKR1B1 4330/4885 |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | TPH1, TPH2, HTR4 | TDP1 503/4885MAPT 1354/4885AKR1B1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.